Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

IMMUTEP LIMITED

INVESTOR PRESENTATION - IMMUTEP LIMITED

ASX:IMM

IMMUTEP LIMITED

Health Care

Immutep Limited are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S. They are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by their Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. Their objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. They have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.

Read more

Market Cap

128.15m

Price at Close

$0.26

4w avg. Volume

1.25m

4w avg. Turnover

$317.77k

Announcements
announcementt+2 movementdate
  • Immutep enters into a Licence & Collaboration with LabCorp

    Progress Report · Market sensitive

  • -

    29 Oct 2020

-

29 Oct 2020
  • Results of Meeting

    Notice Of Meeting

  • 0.00%

    27 Oct 2020

0.00%

27 Oct 2020
  • Chairman's AGM Address

    Chairman's Address

  • 0.00%

    26 Oct 2020

0.00%

26 Oct 2020
  • 2020 AGM Presentation

    Periodic Reports · Market sensitive

  • 0.00%

    26 Oct 2020

0.00%

26 Oct 2020
  • COVID-19 phase 2 investigator initiated trial commences

    Progress Report · Market sensitive

  • +4.00%

    22 Oct 2020

+4.00%

22 Oct 2020
  • Immutep Quarterly Activities Report & Appendix 4C

    Commitments test entity quarterly reports · Market sensitive

  • -5.45%

    21 Oct 2020

-5.45%

21 Oct 2020
  • Immutep granted European patent for IMP761

    Progress Report · Market sensitive

  • -5.45%

    21 Oct 2020

-5.45%

21 Oct 2020
  • Immutep to present AIPAC Overall Survival data at SABCS 2020

    Company Administration

  • +10.00%

    18 Oct 2020

+10.00%

18 Oct 2020
  • Change in substantial holding

    Shareholder Details

  • 0.00%

    05 Oct 2020

0.00%

05 Oct 2020
  • Change of Director's Interest Notice - Mr Chamberlain

    Shareholder Details

  • 0.00%

    05 Oct 2020

0.00%

05 Oct 2020
Market Data

Current Price

$0.26

52WK HIGH

$0.495

52WK LOW

$0.027

1YR RETURN

+828.57%

1YR RETURN VS. SECTOR

+810.97%

90 DAY RETURN

+36.84%

ASX RANK

693

/2,013

SECTOR RANK

12

/47

SHARES OUTSTANDING

492.87m
ASX:IMM

IMMUTEP LIMITED

Health Care

Immutep Limited are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S. They are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by their Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. Their objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. They have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.

Read more

Market Cap

128.15m

Price at Close

$0.26

4w avg. Volume

1.25m

4w avg. Turnover

$317.77k

ASX:IMM is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.